Keith Regnante

Insider Reports History

Entity
Individual
Location
733 Concord Avenue, Cambridge, MA
Signature
/s/ Keith Regnante
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Keith Regnante:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Keros Therapeutics, Inc. CHIEF FINANCIAL OFFICER Employee Stock Option (right to buy) 40K Feb 13, 2024 Direct
Keros Therapeutics, Inc. CHIEF FINANCIAL OFFICER Common Stock 0 $45.29 Nov 4, 2023 Direct

Insider Reports Filed by Keith Regnante

Symbol Company Period Transactions Value $ Form Type Date Filed Role
KROS Keros Therapeutics, Inc. Feb 13, 2024 1 $0 4 Feb 15, 2024 CHIEF FINANCIAL OFFICER
KROS Keros Therapeutics, Inc. Nov 4, 2023 3 -$1.17M 4 Jan 8, 2024 Chief Financial Officer
KROS Keros Therapeutics, Inc. Jun 8, 2023 9 -$1.22M 4 Jun 12, 2023 Chief Financial Officer
KROS Keros Therapeutics, Inc. Feb 16, 2023 1 $0 4 Feb 17, 2023 Chief Financial Officer
KROS Keros Therapeutics, Inc. Jan 21, 2022 1 $0 4 Jan 25, 2022 Chief Financial Officer